Ancrod stroke program

Outcome Measures. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. Neurobiological Technologies. More Information. Additional Information: Related Info. Stroke Fibrinogen Reperfusion Thrombolysis. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Stroke Cerebral Ischemia Brain Infarction. Drug: Ancrod Viprinex Drug: Placebo. Phase 3. Study Type :. Conclusions: These results demonstrate that intravenous ancrod starting within 6 hours after symptom onset in a broad selection of subjects with ischemic stroke did not improve their outcome and revealed a trend to increased bleeding despite successful efforts to achieve rapid initial defibrinogenation and avoid prolonged hypofibrinogenemia.

Abstract Background and purpose: Previous studies of multiple-day dosing with the defibrinogenating agent, ancrod, in acute ischemic stroke yielded conflicting results but suggested that a brief dosing regimen might improve efficacy and safety. Substances Fibrinolytic Agents Placebos Ancrod. The data sets from these studies provide an opportunity to determine whether ancrod-related variables are associated with efficacy and safety.

Objective: This post hoc analysis of data from the Stroke Treatment with Ancrod Trial STAT analyzed ancrod-related variables as potential determinants of efficacy or safety. Methods: The relationships between ancrod-related variables and the outcomes of efficacy and symptomatic intracranial hemorrhage ICH were analyzed using a 3-stage multivariate process.